An American Thoracic Society-led international task force has released a guidance document to help clinicians manage COVID-19 patients in the face of a worldwide pandemic and minimal empirical evidence to guide treatment.
While the guidance includes suggestions relevant to all patients with COVID-19, ranging from outpatients to critically ill patients, most of the suggestions target hospitalized patients with COVID-19 pneumonia.
- Extracorporeal membrane oxygenation (ECMO) to be considered if prone ventilation fails for patients with refractory hypoxemia due to progressive COVID‐19 pneumonia (i.e., ARDS)
- Prone ventilation is suggested for patients with refractory hypoxemia due to progressive COVID-19 pneumonia (i.e., ARDS)
- The evidence that exists around the use of hydroxychloroquine and chloroquine is contradictory.
- The task force made no suggestions for or against treatment with remdesivir, lopinavir, ritonavir, tocilizumab, or systemic corticosteroids.
Disclaimer: Because the guidance is not based on high quality empirical evidence - since COVID-19 is an emerging disease - the task force made suggestions as opposed to recommendations. The suggestions should not be considered mandates and will be revisited as evidence accumulates. These are suggestions and should not replace clinical judgement at the bedside.
About the American Thoracic Society
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
Please find detailed suggestions in the posters attached below.
Note: This list is a brief compilation of some of the key recommendations included in the Guideline and is not exhaustive and does not constitute medical advice. Kindly refer to the original document attached below.